These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 25869258)

  • 1. Information Concerning Endocrine Therapy and Adherence of Patients with Breast and Prostate Cancer.
    Linke B; Liebl P; Marten D; Stoll C; Jung B; Wuensch P; Huebner J
    Clin Oncol (R Coll Radiol); 2015 Aug; 27(8):482-3. PubMed ID: 25869258
    [No Abstract]   [Full Text] [Related]  

  • 2. Special issue on steroids and cancer. Preface.
    Geisler J; Sasano H
    J Steroid Biochem Mol Biol; 2012 Sep; 131(3-5):67. PubMed ID: 22732368
    [No Abstract]   [Full Text] [Related]  

  • 3. Current topics and perspectives in the treatment of endocrine-related cancers.
    Iwase H
    Int J Clin Oncol; 2008 Oct; 13(5):377-9. PubMed ID: 18946746
    [No Abstract]   [Full Text] [Related]  

  • 4. [Mechanism and side effect of endocrine therapy].
    Tsuda M; Ishiguro H; Saji S
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():291-7. PubMed ID: 25831770
    [No Abstract]   [Full Text] [Related]  

  • 5. Educational tool-kit on diet and exercise: survey of prostate cancer patients about to receive androgen deprivation therapy.
    Lebret T; Coloby P; Descotes JL; Droupy S; Geraud M; Tombal B
    Urology; 2010 Dec; 76(6):1434-9. PubMed ID: 21130255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Goserelin (Zoladex) or orchiectomy in metastatic prostate cancer? A quality of life and cost-effectiveness analysis.
    Nygård R; Norum J; Due J
    Anticancer Res; 2001; 21(1B):781-8. PubMed ID: 11299844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neoadjuvant hormone therapy with casodex in a dose 150 mg prior to radical prostatectomy in patients with prostatic cancer].
    Rusakov IG; Petrov SB; Alekseev BIa; Veliev EI
    Urologiia; 2004; (4):15-9. PubMed ID: 15457946
    [No Abstract]   [Full Text] [Related]  

  • 8. [Adjuvant cancer therapy].
    Heinrich B
    MMW Fortschr Med; 2010 Oct; 152(41):36. PubMed ID: 21090374
    [No Abstract]   [Full Text] [Related]  

  • 9. Hormone agonists and antagonists in the treatment of hormone sensitive breast and prostate cancer.
    Nicholson RI; Walker KJ; Davies P
    Cancer Surv; 1986; 5(3):463-86. PubMed ID: 3555778
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of hormonal manipulations in patients with hormone-sensitive metastatic breast cancer.
    Bodmer A; Castiglione-Gertsch M
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S28-37. PubMed ID: 21943985
    [No Abstract]   [Full Text] [Related]  

  • 11. The importance of nonpharmacogenetic factors in endocrine therapy.
    McCowan C; Thompson AM
    Pharmacogenomics; 2012 Apr; 13(6):721-8. PubMed ID: 22515614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [An overview of clinical trials in endocrine therapy for cancer].
    Hinotsu S; Ohasi Y; Akaza H
    Gan To Kagaku Ryoho; 1996 May; 23(6):689-94. PubMed ID: 8645019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Endocrine therapy of solid tumors].
    Possinger K; Grosse Y; Petrides PE
    Internist (Berl); 1998 Nov; 39(11):1123-30. PubMed ID: 9859046
    [No Abstract]   [Full Text] [Related]  

  • 14. Metabolic effects of hormone deprivation therapy: weighing the evidence.
    Van Londen GJ; Lembersky BC
    Oncology (Williston Park); 2010 Aug; 24(9):846-7. PubMed ID: 20923042
    [No Abstract]   [Full Text] [Related]  

  • 15. Cancer treatments and their side effects are associated with aggravation of insomnia: Results of a longitudinal study.
    Savard J; Ivers H; Savard MH; Morin CM
    Cancer; 2015 May; 121(10):1703-11. PubMed ID: 25677509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer treatment-induced bone loss in breast and prostate cancer.
    Saad F; Adachi JD; Brown JP; Canning LA; Gelmon KA; Josse RG; Pritchard KI
    J Clin Oncol; 2008 Nov; 26(33):5465-76. PubMed ID: 18955443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence rates and correlates in long-term hormonal therapy.
    Dunn J; Gotay C
    Vitam Horm; 2013; 93():353-75. PubMed ID: 23810015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hormones and antihormones, cancer of the breast and prostate, escape and treatment].
    André J
    Ann Endocrinol (Paris); 2003 Oct; 64(4):350-1. PubMed ID: 14595252
    [No Abstract]   [Full Text] [Related]  

  • 19. Informing women with breast cancer about endocrine therapy: effects on knowledge and adherence.
    Heisig SR; Shedden-Mora MC; von Blanckenburg P; Schuricht F; Rief W; Albert US; Nestoriuc Y
    Psychooncology; 2015 Feb; 24(2):130-7. PubMed ID: 24953538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating asymptomatic patients with hormone-refractory prostate cancer: hormonal manipulations for the urologist.
    Boudreaux KJ; Chang SS
    BJU Int; 2008 Mar; 101(6):671-4. PubMed ID: 18070172
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.